Belsham, G.J., Jamal, S.M., Tjornehoj, K., Botner, A., Rescue of foot-and-mouth disease viruses that are pathogenic for cattle from preserved viral RNA samples. PLoS One, 6, 2011, e14621.
Diaz-San, S.F., Weiss, M., Perez-Martin, E., Koster, M.J., Zhu, J., Grubman, M.J., de Los, S.T., Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology. 413 (2011), 283–292.
Domingo, E., Escarmis, C., Baranowski, E., Ruiz-Jarabo, C.M., Carrillo, E., Nunez, J.I., Sobrino, F., Evolution of foot-and-mouth disease virus. Virus Res. 91 (2003), 47–63.
Feld, J.J., Hoofnagle, J.H., Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 436 (2005), 967–972.
Golde, W.T., Pacheco, J.M., Duque, H., Doel, T., Penfold, B., Ferman, G.S., Gregg, D.R., Rodriguez, L.L., Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23 (2005), 5775–5782.
Khan, M., Dhanwani, R., Patro, I.K., Rao, P.V., Parida, M.M., Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res. 89 (2011), 1–8.
Kim, S.M., Park, J.H., Lee, K.N., Kim, S.K., Ko, Y.J., Lee, H.S., Cho, I.S., Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-alpha and antiviral agents. Antiviral Res. 96 (2012), 213–220.
Li, S.F., Gong, M.J., Sun, Y.F., Shao, J.J., Zhang, Y.G., Chang, H.Y., In vitro and in vivo antiviral activity of mizoribine against foot-and-Mouth disease virus. Molecules., 24, 2019, 1723.
Marcellin, P., Horsmans, Y., Nevens, F., Grange, J.D., Bronowicki, J.P., Vetter, D., Purdy, S., Garg, V., Bengtsson, L., McNair, L., Alam, J., Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J. Hepatol. 47 (2007), 476–483.
Markland, W., McQuaid, T.J., Jain, J., Kwong, A.D., Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44 (2000), 859–866.
Moraes, M.P., de Los, S.T., Koster, M., Turecek, T., Wang, H., Andreyev, V.G., Grubman, M.J., Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J. Virol. 81 (2007), 7124–7135.
Olschlager, S., Neyts, J., Gunther, S., Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res. 91 (2011), 89–93.
Rustgi, V.K., Lee, W.M., Lawitz, E., Gordon, S.C., Afdhal, N., Poordad, F., Bonkovsky, H.L., Bengtsson, L., Chandorkar, G., Harding, M., McNair, L., Aalyson, M., Alam, J., Kauffman, R., Gharakhanian, S., McHutchison, J.G., Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology 50 (2009), 1719–1726.
Tong, X., Smith, J., Bukreyeva, N., Koma, T., Manning, J.T., Kalkeri, R., Kwong, A.D., Paessler, S., Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antiviral Res. 149 (2018), 34–40.
Usharani, J., Park, S.Y., Cho, E.J., Kim, C., Ko, Y.J., Tark, D., Kim, S.M., Park, J.H., Lee, K.N., Lee, M.H., Lee, H.S., Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus. Antiviral Res. 143 (2017), 134–141.
Westover, J.B., Sefing, E.J., Bailey, K.W., Van Wettere, A.J., Jung, K.H., Dagley, A., Wandersee, L., Downs, B., Smee, D.F., Furuta, Y., Bray, M., Gowen, B.B., Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res. 126 (2016), 62–68.
